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ORIGINAL ARTICLE
Background/Aims: Peroxiredoxin (Prx) belongs to a ubiquitous family of antioxidant enzymes that regulates
many cellular processes through intracellular oxidative signal transduction pathways. Silica-induced lung damage
involves reactive oxygen species (ROS) that trigger subsequent toxic effects and inflammatory responses in
alveolar epithelial cells resulting in fibrosis. Therefore, we investigated the role of Prx in the development of lung
oxidant injury caused by silicosis, and determined the implication of ROS in that process. 
Methods: Lung epithelial cell lines A549 and WI26 were treated with 1% silica for 0, 24, or 48 hours, following pre-
treatment of the A549 cells with N-acetyl-L-cysteine and diphenylene iodonium and no pretreatment of the WI26
cells. We transfected an HA-ubiquitin construct into the A549 cell line and then analyzed the cells via Western
blotting and co-immunoprecipitation.
Results: Silica treatment induced cell death in the A549 lung epithelial cell line and selectively degraded Prx I
without impairing protein synthesis in the A549 cells, even when the ROS effect was blocked chemically by N-
acetyl-L-cysteine. A co-immunoprecipitation study revealed that Prx I did not undergo ubiquitination.
Conclusions: Silica treatment induces a decrease of Prx I expression in lung epithelial cell lines regardless of the
presence of ROS. The silica-induced degradation of Prx does not involve the ubiquitin-proteasomal pathway.
(Korean J Intern Med 2009;24:220-226)
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INTRODUCTION
Silicosis is a disease that affects quarry workers,
stonemasons, and industrial workers who are exposed
continuously to silicon particles in poorly ventilated
working environments. Silicosis is a chronic pulmonary
fibrotic disease that is caused by the persistent aspiration
of dust containing crystalline silica. Aspirated silica can
lead to cell death and tissue damage via phagocytosis by
pulmonary macrophages that cannot digest these inor-
ganic particles and thus produce reactive oxygen species
(ROS) continuously. This destructive cycle results in the
proliferation of fibroblasts and fibrotic scars to replace the
damaged lung tissue caused by silica-induced pathologic
processes [1,2].
Oxidative stress is involved in silica-induced pathog-
enesis by releasing ROS and may have other cellular toxic
effects [3,4]. The exact mechanism by which silicosis
occurs has yet to be elucidated. ROS comprises a class of
ubiquitous molecules that include the superoxide anion
(O2), hydrogen peroxide (H2O2), the hydroxyl radical
(OH), and ROOH, all of which are produced either by
normal cellular respiration processes or during the course
of normal cellular signal transduction cascades such asLee HL, et al. Decreased expression of peroxiredoxins induced by silica    221
cell growth and differentiation [5]. ROS also protects
human tissues against pathogen- and foreign body-
induced damage by activating powerful antiseptics [6-8].
However, in excess, ROS are toxic oxygen free radicals
that cause the oxidative damage involved in aging and cell
injury [9]. 
Peroxiredoxin (Prx), a 25-kDa enzyme first detected in
yeast, belongs to a relatively new family of peroxidases
and is expressed ubiquitously in all living organisms. One
role for Prx is to reduce H2O2 and alkyl hydroperoxide to
water (H2O) and alcohol via a catalytic system that uses
thioredoxin (Trx), Trx reductase (TR), and NADPH [10,11].
Prx also plays an important role in controlling secondary
signal transduction molecules by regulating low concen-
trations of H2O2[5]. 
Although the function and expression of Prx have been
reported, few studies have examined the mechanism of
Prx proteolysis. Our objective herein was to determine the
role of Prx in lung oxidant injuries caused by silicosis and
to determine how ROS is implicated in that process. To
this end, we aimed to verify the proteolytic mechanism of
silicosis.
METHODS
Recombinant DNA
We amplified the complete ubiquitin cDNA sequence
using polymerase chain reaction (PCR) for one cycle at 95˚C
for 1 minutes, 37˚C for 1 hours, and 72˚C for 1 minutes. The
human brain cDNA library (Invitrogen Life Technologies,
Carlsbad, CA, USA) was used as a template from which
ubiquitin was amplified using the following primers:
forward, 5’-GCGGCCGCATGCAGATCTTCGTGAAGA-3’,
and reverse, 5’-GCGGCCGCTTACCCACCTCTGAGACGGAG-
3’. The PCR conditions consisted of 30 cycles at 95˚Cfor
1 minutes, 55˚C for 1 minutes, and 72˚C for 1 minutes,
followed by a final extension at 72˚C for 10 minutes. The
amplified ubiquitin gene was ligated into the pGEM
®-T
Easy Vector (Promega, Madison, WI, USA) using T4 DNA
ligase (Invitrogen Life Technologies, Carlsbad, CA, USA).
The HA-tagged ubiquitin construct was produced by first
excising the ubiquitin gene using the restriction enzymes
ApaI and SalI (New England Biolabs, Beverly, MA, USA)
and subsequently ligating the fragment into the pCMV-
HA vector (Clontech, Mountain View, CA, USA).
Materials and methods
We used the WI26 and A549 cell lines (ATCC, Rockville,
MD, USA) originating from type I and II human pul-
monary epithelial cancer cells, and the Raw264.7 cell
line (ATCC) originating from a mouse peritoneal
macrophage cell population. The cells were cultured in
the appropriate culture media as recommended by ATCC
at 37˚C under 5% CO2 in 10% fetal bovine serum (Gibco
BRL, Gaithersburg, MD, USA), in Dulbecco’s modified
Eagle’s medium (Gibco BRL, Gaithersburg, MD, USA),
or in RPMI1640 (Gibco BRL, Gaithersburg, MD, USA)
culture medium. The culture medium was exchanged
for fresh medium every 3 days. When the cells reached
confluency, the cultures were trypsinized using 0.25%
trypsin/ethylenediamine tetraacetic acid (EDTA; Gibco
BRL, Gaithersburg, MD, USA) and divided.
In addition, we observed the expression of Prx in
patients with silicosis combined with lung cancer. 
Treatment of cell lines with silica and ROS blockage
In the first experiment, the A549 and WI26 cell lines
were treated with 1% silica (Sigma, St. Louis, MO, USA)
for 0, 24, or 48 hours and harvested for examination. In a
second experiment, A549 cells were pretreated with
Nacetyl-L-cysteine (NAC; Sigma, St. Louis, MO, USA) and
diphenyleneiodonium (DPI; Calbiochem, Darmstadt,
Germany) for 1 hours to prevent the accumulation of ROS.
The cells were then treated with 1% silica, harvested, and
examined at 24 and 48 hours posttreatment. In a third
experiment, we added a proteosome inhibitor, 10 µM MG-
132 (Calbiochem, Darmstadt, Germany), to the silica-
treated cells 12 hours before we harvested the cell
populations. 
Transfection of HA-ubiquitin into the A549 cell line
The A549 cell cultures were established and stabilized
24 hours before they were transfected with the ubiquitin
constructs. The culture medium was exchanged, and the
HA-ubiquitin plasmid (20 µg) was transfected into the
A549 cells (ubiquitin-A549) using Lipofectamine
TM 2000
(Invitrogen Life Technologies, Carlsbad, CA, USA). After
24 hours, the transfected cells were treated with silica
and MG-132.
Western blots
We extracted the total protein populations from the
cell samples using protein lysis buffer (20 mM Tris [pH
7.4], 1 mM EDTA, 1 mM EGTA, 100 mM NaCl, 5 µg/mL222 The Korean Journal of Internal Medicine Vol. 24, No. 3, September 2009
leupeptin, 10 µg/mL aprotinin), and the extraneous debris
was precipitated by centrifuging at 12,000 rpm for 10
minutes. The protein concentration in the supernatant
was quan-tified using the Bradford reagent assay (Bio-
Rad, Hercules, CA, USA). The proteins were separated
using sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) in 12% SDS gels and then
transferred to nitrocellu-lose membranes. To identify
the proteins of interest, we used primary antibodies,
including a polyclonal antibody against each Prx type (I-
VI; Labfrontier, Seoul, Korea), a monoclonal anti-HA
antibody (Sigma), and a mono-clonal anti-IκB-α antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Secondary antibodies included peroxidase-conjugated
sheep anti-mouse and donkey anti-rabbit antibodies, and
enhanced chemiluminescence (Amersham Biosciences,
Buckinghamshire, UK) was used to detect the proteins.
Co-immunoprecipitation
To find evidence of Prx-ubiquitination, we performed a
co-immunoprecipitation experiment that overexpressed
the Prx isoforms or the ubiquitin protein in A549, HeLa,
and Wi26 cells. We have attempted to overexpress PrxI
in various cell lines. However, for unknown reason, over-
expression was not successful. Therefore we have changed
our strategy to overexpress ubiquitin instead and per-
formed co-immunoprecipitation of Prx I and ubiquitin.
After overexpressing ubiquitin in the aforementioned cell
lines, we grew the cells in their appropriate culture media
to full confluency under the aforementioned culture
conditions. The cells were then harvested by trypsining (as
before, with 0.25 trypsin/EDTA solution) and were lysed
by adding homogenization/lysis buffer (20 mM Tris [pH
7.4], 1 mM EDTA, 1 mM EGTA, 100 mM NaCl, 5 µg/mL
leupeptin, 10 µg/mL aprotinin). The lysate was centrifuged
on a tabletop microcentrifuge at 4,000 rpm and only the
supernatant was used for the subsequent experiment.
We purified the protein samples from the A549 cells. The
co-immunoprecipitation experiment was performed by
adding 20 µL of protein A agarose (Upstate, Charlottesville,
VA, USA), allowing it to react for 1 hours at 4˚Cwith gentle
shaking, and separating by centrifugation at 4,000 rpm
for 5 minutes. The supernatant was mixed with the anti-
HA antibody (2 µg) and allowed to react for 2 hours at
4˚C with gentle shaking. Protein A agarose (20 µL) was
then added to the co-immunoprecipitation samples and
allowed to react for 1 hours. The immunoprecipitate was
collected by centrifugation at 4,000 rpm for 5 minutes at
4˚C. The pellet was washed with protein lysis buffer and
centrifuged at 4,000 rpm at 4˚C. This process was repeated
five times to ensure purity of the precipitate. The sample
buffer (1×) was added to the immunoprecipitated sample.
Afterward, the resultant samples were electrophoresed (10
µL/lane) and immunoblotted with the primary antibodies. 
This study was approved by the Institutional Review
Board of Ajou University Hospital.
RESULTS
Expression of Prx isoforms in lung cells
The expression patterns of the Prx isoforms differed
between the human pulmonary epithelial cell lines (A549
and WI26) and the other tested cell lines (the Raw264.7,
mouse cell line; and the Rat2, rat cell line). Prx I and Prx
III-VI were all expressed in the A549 cell line originating
from type II human pulmonary epithelial cells, but only a
low level of Prx II, an antioxidant protein in yeast and
human red blood cells, was expressed. All of the Prx
isoforms were differentially expressed in various cell lines
in this study. Prx I and Prx III-VI were all expressed in
the A549 cell with minimal expression of Prx II. All Prx
isoforms were expressed in the WI26 cell line. Prx I-III
and Prx V, but neither Prx IV nor Prx VI, were detected
in the Raw 264.7 macrophage cell line(Fig. 1).
Figure 1. Expression of Prx isoforms in lung cells. Various cell
lines (A549, Raw264.7, and WI26) were lysed, and 10 µg/lane of
the total protein extract was loaded onto 12% reducing SDS-
PAGE gels that were then subjected to Western blot analysis
with Prx isoform-specific antibodies. All of the Prx isoforms
were differentially expressed in various cell lines in this study.
Prx I and Prx III-VI were all expressed in the A549 cell with
minimal expression of Prx II. All Prx isoforms were expressed
in the WI26 cell line. Prx I-III and Prx V, but neither Prx IV nor
Prx VI, were detected in the Raw 264.7 macrophage cell line.
Abbreviations : NL=normal lung tissue, A 549=A549 lung
cancer cell line, WI 26=WI 26 type I epithelial cell line,
RAW=RAW 264.7 cell line, Rat 2=Rat 2 fibroblast cell line. 
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Change in Prx expression with silica treatment in
Type I and II human alveolar epithelial cell lines
The A549 (type II) and WI26 (type I) cells were
exposed progressively to 1% silica for 0, 24, or 48 hours,
and any changes in Prx expression levels were observed
and noted. In A549 cells, silica treatment caused a
reduction in the expression of Prx I (Fig. 2A). In WI26
cells, silica treatment reduced the expression of Prx I and
II while other Prx isoforms were intact (Fig. 2B). 
Analysis of the mechanism of silica-induced
alteration of Prx expression
To confirm the relationship between the silica-induced
expression of Prx and activation of ROS (silica at 1
mg/mL, 48 hours), we used NAC (1 mM, 48 hours) and
DPI (1 µM, 48 hours) to remove ROS from the activated
proteins linked to the oxidation-reduction (redox)
reactions of the NADPH oxidase system. Silica treatment
of the cell samples reduced the levels of Prx expression
regardless of pretreatment with ROS inhibitors, whereas
the control samples showed decreased expression of
IκB-α, a com-pound that is decreased by ROS-induced
protein degra-dation. Reduction of Prx expression was
only dependent on the presence of silica treatment
regardless of other effects of ROS (Fig. 3). Thus, it appears
that the silica-induced decrease on Prx expression might
not be associated with ROS but could be the result of a
specific effect or direct action on the Prx protein itself. 
A B
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Prx III
Prx IV
Prx V
Prx VI
IκB-α
β-actin
Silica
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Figure 3. Effects of NAC and DPI on silica-induced degradation
of Prx I and IκB-α in A549 cells. Cells were incubated for 1
hours in the presence or absence of 1 mM NAC or 1 µM DPI,
and then for 48 hours with or without silica (1 mg/mL). Cell
lysates were subjected to Western blot analysis with primary
antibodies. Silica treatment of the cell samples reduced the
levels of Prx expression regardless of pretreatment with ROS
inhibitors, whereas the control samples showed decreased
expression of IκB-α, a compound that is decreased by ROS-
induced protein degradation. Reduction of Prx expression was
only dependent on the presence of silica treatment regardless of
other effects of ROS. Abbreviations: NAC=N-acetylcysteine,
DPI=diphenyleneiodo-nium.
IκB-α
Prx I
β-actin
NAC  (1 mM, 48 h)
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Figure 4. Effects of MG-132 on silica-induced degradation of
Prx I in A549 cells. Cells were incubated for 12 hours in the
presence or absence of MG-132 (10 µM) and then incubated
with or without silica (1 mg/mL) for the indicated times. Cell
lysates were subjected to Western blot analysis with primary
antibodies. The decreased expression of Prx I induced by
treatment with 1% silica in A549 cells was affected by the
addition of MG-132, a potent ubiquitin-proteasomal degradation
pathway inhibitor. Abbreviations: MG-132=MG-132 proteosome
inhibitor.
Prx I
IκB-α
Time
MG-132 (10 µM)
Silica (1 mg/mL)
0 h 24 h 48 h
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- - ++++
Figure 2. Effect of silica on the abundance of Prx isoforms (Prx
I - VI) in lung epithelial cell lines. (A) A549 cells were exposed to
silica (1 mg/mL) for the indicated times, after which the cell
lysates (10 µg or 30 µg of protein per lane) were subjected to
Western blot analysis with primary antibodies. (B) WI26 cells
were exposed to silica (1 mg/mL) for the indicated times. The
samples were treated in the same way as in described for (A). In
A549 cells, silica treatment caused a reduction in the expression
of Prx I. In WI26 cells, silica treatment reduced the expression
of Prx I and II while other Prx isoforms were intact. 224 The Korean Journal of Internal Medicine Vol. 24, No. 3, September 2009
Analysis of silica-induced Prx degradation
The decreased expression of Prx I induced by treatment
with 1% silica in A549 cells was affected by the addition
of MG-132, a potent ubiquitin-proteasomal degradation
pathway inhibitor (Fig. 4). To determine whether the
protease was recovered by proteasomes because of
ubiquitination inactivation, we examined the amount of
Prx I in the A549 cells over-expressing ubiquitin (ubiquitin-
A549) by measuring the amount of Prx I bound to
ubiquitin via immunoprecipi-tation. The effects of silica
were not prevented by the addition of MG-132 to cells
overexpressing ubiquitin (Fig. 5A), Only Lipofectamine
TM
2000, which was used to obtain cells overexpressing
ubiquitin, contributed to a minor decrease in the expression
of Prx I (Fig. 5B). Immunoprecipitation did not detect
binding between ubiquitin and Prx I indicating no
ubiquitination of Prx 1 in cells (Fig. 6). 
DISCUSSION
We observed decreased Prx expression levels in the
Figure 5. Effects of MG-132 on silica-induced degradation of Prx I in ubiquitin-A549. (A) A549 cells were transfected with the HA-
ubiquitin construct. After 24 hours, the cells were cultured in the presence of silica and/or MG-132 for the indicated times. Cell lysates
were subjected to Western blot analysis with primary antibodies. (B) The cells were harvested at the indicated times after being
transfected with the HA-ubiquitin construct. The effects of silica were not prevented by the addition of MG-132 to cells overexpressing
ubiquitin. Only LipofectamineTM 2000, which was used to obtain cells overexpressing ubiquitin, contributed to a minor decrease in
the expression of Prx I. Abbreviations : HA 549=Hemaglutinin overexpressing A549, ub-549=ubquitin-overexpressing A549.
Difference of beta actin size in the figure is due to partial protein degradation following silica treatment.
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Figure 6. Identification of the interaction between ubiquitin
and Prx I in A549 cells by co-immunoprecipitation.
Ubiquitin-A549 lysates were co-immunoprecipitated with
anti-HA and reacted with anti-HA and anti-Prx I antibodies.
Immunoprecipitation did not detect binding between ubiquitin
and Prx I indicating no ubiquitination of Prx 1 in cells.
Abbreviations : HA 549=Hemaglutinin overexpressing A549, ub-
549=ubquitinoverexpressing A549
Silica (1 mg/mL)
Prx I
HA
0 h
HA-A549
(control)
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A549 cells following silica treatment, regardless of the
presence of ROS. However, the responsible degradation
pathway was not mediated via the ubiquitin-proteasome
route. ROS, including H2O2, can act as second messengers
in signal transduction [12]. Excessive ROS can be detri-
mental to living organisms because ROS release triggers
the modification of proteins, lipid membranes, chromo-
somes, and nucleic acids via oxidative stress, which is
reportedly linked to senescence and inflammation [9]. 
The protein Prx, which plays a pivotal role in removing
H2O2, is present ubiquitously in large amounts in every
living organism from bacteria, yeast, and fungi to higher
mammalian cells [6-8]. Although the exact roles of Prx
in signal transduction, cellular proliferation, carcino-
genesis, and protein chaperoning among living cells are
unclear, the oxidation and reduction of sulfhydryl residues
on the Prx protein may act as a molecular on-off signal,
similar to protein phosphorylation and dephosphorylation,
which serve as molecular switches of protein activation
[13].
Six isoforms of Prx have been identified in mammals.
Prx I and II are cytoplasmic, although small amounts of
these isoforms have been detected in the nucleus. Prx III
occurs only in mitochondria; Prx IV is produced in the
endoplasmic reticulum and is secreted from cells; and
Prx V is found either in lysosomes or in peroxisomes.
Unlike the other Prx isoforms, Prx VI is an atypical subtype
because it contains only one cysteine residue, and no
electron donor has been identified [6,10,11].
Recent reports have helped to elucidate the role of Prx
in antioxidative functions and signal transduction, as
well as a possible role for this protein in the pathogenesis
of many disease processes including breast cancer, skin
diseases, lung cancer, radiation resistance, and RBC
survival [14-20]. Most researchers have focused on the
expression, function, and interactions of the Prx isoforms.
However, few studies have been attempted to examine
the trafficking and degradation of the Prx protein. 
The goal of our study was to observe the silica-induced
decrease in the expression and degradation of Prx protein
levels. We found that the rate of decreased Prx expression
was slower than that reported by Seo et al. [21]. This
discrepancy arose presumably from differences in the
characteristics of the cell lines used. Pulmonary epithe-
lium is continually exposed to external air and thus
constantly interfaces with oxidative stress components.
Therefore, epithelial cells are equipped with protective
mechanisms to survive under harsh oxidative stress
conditions. Because the alveolar epithelium undergoes
silicosis pathology, cell lines of epithelial origin such as
A549 and WI26 are ideal for testing the effects of silica
treatment on Prx expression. Following their examination
of Prx expression levels after treating cells with MG-132,
Seo et al. suggested that the proteasomal pathway is not
involved in Prx degradation [21]. Herein we provide
strong evidence that Prx is not ubiquitinized in pulmonary
epithelial cell lines. Therefore, it is possible that Prx is
degraded via the lysosomal pathway because Prx degrada-
tion did not occur via the ubiquitin-proteasomal pathway. 
Our preliminary findings demonstrate that there is no
decrease in Prx levels upon treatment with tumor necrosis
factor alpha, which induces strong protein degradation
(data not shown). This result indirectly suggests that Prx
functions as a consistent and stable protein for cellular
homeostasis, cellular protection, and the maintenance of
the signal transduction system.  
A previous study by Rhee indicated that Prx has a long
half-life and coordinates closely with a regeneration
system via an electrolyte transfer mechanism through Trx,
TR, and NADPH [22]. The stability and consistency of
Prx is further supported by evidence that when Prx is
converted to peroxidated sulfinic acid, once considered
an irreversible reaction, it can be reduced and regenerated
by sulphiredoxin [22,23].
The release of molecules such as ROS, nitrous oxide
systems, and tumor necrosis factor alpha triggered by
silica inhalation can cause further injury to pulmonary
macrophages, resulting in the proliferation of fibroblasts
in the regeneration process [3,4,24-27]. A silica-induced
decrease in Prx levels may be related to this pathogenic
process. Nevertheless, silicosis pathogenesis was not
fully elucidated by our experiments, and further research
to determine the role(s) of Prx in this vital process is
required.
Our study has several limitations. First, due to techni-
cal difficulties we did not perform microscopic obser-
vations that may verify Prx degradation. Second, we could
not perform our experiments using caspase to explore
apoptosis as a possible explanation for Prx degradation
because the silica reacts with the culture media and ren-
ders caspase evaluations virtually impossible. However,
to confirm whether silica causes apoptosis, another exper-
iment is ongoing with other cell lines to explore relevant
caspase activities. Third, we did not detect a decrease in
the expression levels of Prx in the human tissue obtained
from the silicosis patients, which contradicts our in vitro226 The Korean Journal of Internal Medicine Vol. 24, No. 3, September 2009
findings in the silica-treated A549 cells (data not shown).
This conflicting observation is likely the result of using
a homogenous single population of A549 cells derived
from type II bronchiolar epithelial cells apart from other
cell types. Tissue samples from patients harbor many
heterogeneous cell types, including type I and type II
alveolar epithelial cells as well as alveolar macrophages,
fibroblasts, and immune competent cells, which could
mask any signs of decline in Prx expression level. In
support of this hypothesis is our previous obser-vation
that lung cancer tissues exhibiting cellular proliferation
showed a marked increase in Prx I [16]. Similarly, fibrob-
lastic proliferation in silicotic lung tissue obtained from
the surgeries reported herein may have concealed a
decrease in Prx I by silica.
In conclusion, our experiments show that silica induces
a decrease of Prx I expression in lung epithelial cell lines
regardless of the presence of ROS, and that the silica-
induced degradation of Prx does not involve the ubiquitin-
proteasomal pathway.
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